Literature DB >> 11684954

Immunohistochemical distinction between primary adenocarcinoma of the bladder and secondary colorectal adenocarcinoma.

H L Wang1, D W Lu, L M Yerian, N Alsikafi, G Steinberg, J Hart, X J Yang.   

Abstract

Primary adenocarcinoma of the urinary bladder sometimes causes a diagnostic dilemma because it can be indistinguishable morphologically from adenocarcinoma of colorectal origin secondarily involving the bladder by metastasis or direct extension. It is much less well studied than conventional urothelial carcinoma and colorectal adenocarcinoma because of its rarity. The current study was specifically designed to investigate whether an important mechanism involved in the pathogenesis of colorectal adenocarcinoma, beta-catenin dysregulation, was also important for the development of primary bladder adenocarcinoma and whether these two morphologically similar tumors could be distinguished immunohistochemically. Formalin-fixed, paraffin-embedded tissues from 17 primary adenocarcinomas of the urinary bladder, 16 colorectal adenocarcinomas involving the bladder, and 10 conventional urothelial (transitional) carcinomas were included in this study. Thirteen of the primary bladder adenocarcinomas were moderately to well differentiated (enteric type) and morphologically indistinguishable from colorectal cancers. The remaining four primary tumors were poorly differentiated (two cases) or of clear cell type (two cases). Immunohistochemical studies using a panel of monoclonal antibodies demonstrated positive nuclear staining for beta-catenin expression in 13 of the 16 (81%) colorectal adenocarcinomas secondarily involving the bladder but in none of the primary adenocarcinomas or the urothelial carcinomas. Instead, positive membranous (and some cytoplasmic) staining was present in all primary bladder tumors with the exception of two poorly differentiated adenocarcinomas where no beta-catenin staining was detected. All secondary colorectal adenocarcinomas stained negatively for CK7 and thrombomodulin (TM), whereas positivity for CK20 was observed in 15 (94%) cases. All urothelial carcinomas stained positively for CK7 and TM, and four of them also for CK20. Primary adenocarcinomas of the bladder showed mixed staining patterns for CK7, CK20, and TM with a positive rate of 65%, 53%, and 59%, respectively. These data indicate that dysregulation of beta-catenin, an important aberration seen in colorectal carcinogenesis, does not appear to play a role in the pathogenesis of the bladder adenocarcinoma. In addition, our data demonstrate that a panel of immunostains, including CK7, CK20, TM, and beta-catenin, is of diagnostic value in differentiating primary bladder adenocarcinoma from secondary adenocarcinoma of colorectal origin.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11684954     DOI: 10.1097/00000478-200111000-00005

Source DB:  PubMed          Journal:  Am J Surg Pathol        ISSN: 0147-5185            Impact factor:   6.394


  24 in total

1.  Primary mucinous adenocarcinoma of the bladder: complete response with FOLFOX-4 regimen.

Authors:  A M Tatli; M Uysal; S S Goksu; D Arslan; S Gunduz; M Ozdogan; H S Coskun; H Bozcuk; B Savas
Journal:  Med Oncol       Date:  2011-10-30       Impact factor: 3.064

2.  Endoluminal metastasis of colon cancer to the urinary bladder via the ureter: report of a case.

Authors:  Andrea Giuliani; Gaspare Galati; Martino Demoro; Michele Scimò; Antonio Ciardi; Luigi Basso
Journal:  Surg Today       Date:  2010-11-03       Impact factor: 2.549

Review 3.  Differentiating rectal carcinoma by an immunohistological analysis of carcinomas of pelvic organs based on the NCBI Literature Survey and the Human Protein Atlas database.

Authors:  Koh Miura; Kazuyuki Ishida; Wataru Fujibuchi; Akihiro Ito; Hitoshi Niikura; Hitoshi Ogawa; Iwao Sasaki
Journal:  Surg Today       Date:  2012-03-23       Impact factor: 2.549

4.  Sustained response of adenocarcinoma of the urinary bladder to FOLFOX plus bevacizumab.

Authors:  Minyuen Teo; Niall C Swan; Ray S McDermott
Journal:  Nat Rev Urol       Date:  2011-04-12       Impact factor: 14.432

5.  Detection of TERT promoter mutations in primary adenocarcinoma of the urinary bladder.

Authors:  Morgan L Cowan; Simeon Springer; Doreen Nguyen; Diana Taheri; Gunes Guner; Maria Angelica Mendoza Rodriguez; Yuxuan Wang; Isaac Kinde; Maria Del Carmen Rodriguez Pena; Christopher J VandenBussche; Mathew T Olson; Isabela Cunha; Kazutoshi Fujita; Dilek Ertoy; Kenneth Kinzler; Trinity Bivalacqua; Nickolas Papadopoulos; Bert Vogelstein; George J Netto
Journal:  Hum Pathol       Date:  2016-03-10       Impact factor: 3.466

6.  Synchronous and metachronous ureteric metastases from adenocarcinoma of the colon.

Authors:  Maitrey Darrad; Samuel Harper; Anju Verghese; John Leveckis; Sanjeev Pathak
Journal:  Int J Clin Oncol       Date:  2011-06-28       Impact factor: 3.402

7.  Metastatic Small Intestinal Cancer of the Urinary Bladder.

Authors:  Teppei Morikawa; Akiteru Goto; Hiroaki Nishimatsu; Masashi Fukayama
Journal:  Case Rep Oncol       Date:  2010-09-14

8.  Primary adenocarcinoma of the renal pelvis, ureter and the urinary bladder: A case report and review of the literature.

Authors:  Xing Xiong; Linghua Jia; Jingen Wang
Journal:  Oncol Lett       Date:  2016-01-26       Impact factor: 2.967

9.  Urachal carcinoma: a pathologic and clinical study of 46 cases.

Authors:  Jasreman Dhillon; Yu Liang; Ashish M Kamat; Arlene Siefker-Radtke; Colin P Dinney; Bogdan Czerniak; Charles C Guo
Journal:  Hum Pathol       Date:  2015-08-12       Impact factor: 3.466

Review 10.  Adenocarcinoma of the urinary bladder.

Authors:  Vipulkumar Dadhania; Bogdan Czerniak; Charles C Guo
Journal:  Am J Clin Exp Urol       Date:  2015-08-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.